A review posted in JAMA Network Open up emphasizes the discrepancy amongst what it fees to generate copyright plus the retail prices sufferers deal with. Despite the small creation expenditures, Novo Nordisk has not publicly disclosed precise figures for copyright or its other product, Wegovy.